Lose the weight.
Keep your life.
Four ways in, one standard of care: a licensed clinician sets and titrates your dose, medication ships from a certified US pharmacy, and the price on the page is the price you pay. From $139/mo.
Compounded by a state-licensed 503A pharmacy from a patient-specific prescription. Not FDA-approved.
Same standard of care. Your choice of tool.
The most-prescribed starting point in the program — a GLP-1 receptor agonist prescribed by a licensed clinician.
A daily tablet that dissolves under the tongue — no needles.
Two appetite pathways instead of one — a dual GIP/GLP-1 receptor agonist.
Dual-pathway GLP-1 class therapy in a daily tablet. No needles, no refrigeration.
Two questions get you there.
Your clinician makes the final call in review — but this is the shape of the decision.
Needle, or no needle?+
The injections are once-weekly with a small insulin-gauge needle — most people find them a non-event after week one. If needles are the reason you'd quit or never start, take the daily tablet and lose nothing on clinical oversight.
Semaglutide, or tirzepatide?+
Semaglutide is the lower-priced starting point. Tirzepatide adds a second appetite pathway — a dual-pathway option your clinician may consider based on your history and response.
What if I pick wrong?+
You can't, really. Your clinician reviews your pick against your history before anything ships, and switching format or molecule later happens inside your care plan — no starting over, no penalty.
Three steps to a plan that fits.
Choose the product and term that fit, then complete a short medical intake. Prefer to talk first? Request a call.
A provider licensed in your state reviews your file and confirms the right molecule and format — or tells you GLP-1 isn't appropriate, free.
Medication arrives from a certified US pharmacy. Your care team guides the ramp, the check-ins, and any dose adjustments.
Deals, new science, and new programs.
Join the list for member pricing, the latest research on hormones and longevity, and first access to new programs.